AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech ...

Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...

Dynavax is paying $30 million upfront for global rights to Vaxart’s investigational oral COVID-19 vaccine candidate, positioning the biotech to see phase 2b data before placing a bigger bet on the ...

Amid the rapidly unfolding saga revolving around Metsera, a judge has denied Pfizer’s request to block Novo Nordisk’s buyout ...

“The actions outlined today will better position us to drive meaningful earnings growth and further strengthen the company to ...

Precision Neuroscience’s brain-computer interface—a wireless device that aims to restore function to people with paralysis—is ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on ...

Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that ...

Novo Nordisk’s CEO won’t comment on whether the Danish company will go even higher in its bidding war for Metsera, but said ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

The news is coming thick and fast for Qiagen. As the molecular diagnostics specialist announced its third-quarter earnings, ...